Insights Into Chronic Lymphocytic Leukemia (CLL) Southeast
Perspectives of community physicians from the Southeast region of the United States on the management of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)
Southeast – July 8, 2020
Faculty Chair
Matthew Davids, MD
Dana Farber Cancer Institute, Boston, MA, US
REPORT TOPICS INCLUDE
- Report providing the insights from a moderated roundtable discussion focusing on treatment of CLL
Disease state and data presentations were developed in conjunction with Dr Matthew Davids from Dana Farber Cancer Institute
Insights on the following CLL therapies were obtained:- acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, BR
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
GEOGRAPHIC REPRESENATION
- The group of advisors comprised community oncologists from the southeast region of the United States
- Community oncologists were invited from Alabama, Georgia, Florida, South Carolina, Tennessee, and Virginia
